Artery- and vein-specific proteins and uses therefor
AssigneeCalifornia Institute of Technology
InventorsHai U. Wang, Zhoufeng Chen, David J. Anderson
Life of this patent
Estimating the term…
Abstract
Arterial and venous endothelial cells are molecularly distinct from the earliest stages of angiogenesis. This distinction is revealed by expression on arterial cells of a transmembrane ligand, called EphrinB2 whose receptor EphB4 is expressed on venous cells. Targeted disruption of the EphrinB2 gene prevents the remodeling of veins from a capillary plexus into properly branched structures. Moreover, it also disrupts the remodeling of arteries, suggesting that reciprocal interactions between pre-specified arterial and venous endothelial cells are necessary for angiogenesis.
Claims10
A method of inhibiting angiogenesis in a mammal suffering from a disease or disorder characterized by undesirable or excessive vascularization or vascular permeability, comprising administering to the mammal an amount of an EphB4 receptor antagonist which is effective for inhibiting angiogenesis in the mammal, wherein the antagonist is selected from:
- (i) an antibody which binds to EphB4;
- and
- (ii) an antibody which binds to Ephrin B2.
A method of treating a solid malignant tumor in a mammal having a solid malignant tumor, comprising administering to the mammal a therapeutically effective amount of an EphB4 receptor antagonist, wherein the antagonist is selected from:
- (i) an antibody which binds to EphB4;
- and
- (ii) an antibody which binds to Ephrin B2.
Dependencies are inferred from the claim text.